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a  b  s  t  r  a  c  t
Diabetes  mellitus  is one  of the  oldest  disorders  that  is rapidly  emerging  as  a global  health
problem.  Soy  genistein  is a legume  that  has numerous  health  beneﬁts.  This  work  aimed
to study  the  effect  of  different  doses  of  genistein  on  histological,  immunohistochemi-
cal and  morphometrical  changes  in  -cells  of  streptozotocin  (STZ)-induced  diabetic  rats
and  to correlate  these  effects  with  plasma  glucose  and  insulin  levels.  Fifty  adult  male
rats  were  divided  into  ﬁve  equal  groups.  Group  I served  as  a control.  Group  II received
genistein.  Group  III  comprised  STZ-induced  diabetic  rats.  Group  IV  diabetic  animals  treated
with low  dosage  genistein.  Group  V  diabetic  animals  treated  with  high  dosage  genistein.
Genistein  was given  for 4  weeks  after  STZ  injection.  Rats were  sacriﬁced  and  pancreatic
specimens  were  taken  for light  and  electron  microscopic  examination.  Blood  samples  were
collected  for  detection  of  serum  glucose  and insulin  levels.  After  diabetic  induction,  the
islets appeared  shrunken  with  cytoplasmic  vacuolation  of their  cells  and  negative  insulin
immunoreaction.  Ultrastructurally,  -cells  showed  darkly  stained  nuclei  with  marked  loss
of  granules.  Morphometrically,  signiﬁcant  loss  of -cells  was  detected.  The  serum  insulin
level  was decreased  with  elevation  in  the  serum  glucose.  High-dose  but not  low-dose  genis-
tein  improved  the  morphology  of  islets  with  increased  insulin  immunoreaction.  Genistein
also signiﬁcantly  decreased  -cells loss  and  improved  glucose  and insulin  levels.  In  conclu-
sion,  genistein  has a protective  effect  on  pancreatic  -cells  damage,  possesses  the ability  to
regenerate -cells  and  improves  serum  levels  of insulin  and  glucose  in  STZ-induced  diabetic
rats in a  dosage-dependent  manner.
©  2015  Saudi  Society  of  Microscopes.  Published  by Elsevier  Ltd.  All  rights  reserved.1. Introduction
Diabetes mellitus (DM) is one of the oldest diseases that
is rapidly emerging as a global health problem [1]. It is
a metabolic state of hyperglycemia resulting from insulin
deﬁciency, insulin resistance or both [2]. World Health
∗ Corresponding author. Tel.: +966 508958883.
E-mail address: emanalimah@yahoo.com (E.A. El-Kordy).
http://dx.doi.org/10.1016/j.jmau.2015.03.005
2213-879X/© 2015 Saudi Society of Microscopes. Published by Elsevier Ltd. All riOrganization (WHO) indicates that DM is one of the major
killers of humans in our time and affect 1–5% of the world
population [3,4]. By the year 2025, the number of individ-
uals with diabetes is predicted to be more than 325 million
in spite of availability of new drugs, techniques and surgical
intervention [5,6].There are two types of DM.  Type 1 (insulin-dependent)
that results from damage of pancreatic insulin producing
cells and type 2 (non-insulin-dependent) that results from
insulin resistance [7]. Among various factors that are being
ghts reserved.
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nvolved in the progression of DM,  oxidative stress plays
mportant role in etiology of DM and related complications
8]. Persistent hyperglycemia is responsible for increasing
ormation of free radicals, autooxidation of glucose and
ipid peroxidation as well as disturbance of the antioxi-
ant defense system. The resultant free radicals bring about
ntracellular oxidative stress [9].
The streptozotocin (STZ) is the most commonly used
gent for experimental animals to produce type 1 diabetes
y selective damage of pancreatic -cells. The STZ enters
he -cells via glucose transporter and causes DNA damage
10].
In humans, islets constitute nearly 1–2% of pancreatic
issue and insulin-secreting -cells represent up to 80% of
ells in islets that have the ability to proliferate in both
hysiological and pathological conditions [11,12]. The bal-
nce between transdifferentiation (differentiation of other
ell types into -cells) and neogenesis (differentiation of
recursor cells into -cells) and proliferation of preexis-
ing -cells are important factors for controlling the mass
f -cells [13].
Based on recent advances, disturbance of regulation of
-cell growth and function are central to the development
f two types of diabetes. Hence, many studies are underway
o ﬁnd new effective agents that can increase or preserve
slet -cell mass and function, providing a plane to lower
he burden of morbidity from DM and its complications
13,14].
Genistein, a naturally occurring soy isoﬂavone is a
avonoid in legumes and some herbal medicines [15]. It has
umerous health effects [16,17] and its intake is considered
afe and nontoxic following pharmacological administra-
ion in rats [18] and humans [19]. Previous studies have
eported the potential roles of genistein on prevention of
ormone-related disorders such as breast cancer, cardio-
ascular diseases, osteoporosis and chronic renal disease
20–23].
Recent studies have reported that administration of
soﬂavone reduced the elevated blood glucose level in dia-
etic animals [24,25] and postmenopausal women [26].
enistein has been extensively reported as a compound
ith many functions through improving the antioxidant
efense system and anti-inﬂammation response [23,27].
owever, the studies of the effect of genistein by itself on
orphology of pancreatic -cells in diabetic animals are
ery limited.
Based on these, we demonstrated in the current study
he possible protective effect of different doses of soy
soﬂavone genistein on histological, immunohistochemi-
al and morphometrical changes in pancreatic -cells of
TZ-induced diabetic rats and correlated these effects with
lasma glucose and insulin levels.
. Materials and methods
.1. ChemicalsSTZ and genistein were obtained from Sigma Chemical
ompany (St. Louis, Missouri, USA).
STZ was freshly dissolved in 5 mmol/l citrate buffer, pH
.5 and given intraperitonium (single injection, 60 mg/kg)opy and Ultrastructure 3 (2015) 108–119 109
[28]. Each 100 mg  of genistein was  dissolved in 10 ml  dis-
tilled water (10 mg/ml) and given orally by gastric tube. The
doses were adjusted on the basis of a previous work [29].
2.2. Animals
Fifty adult male albino rats with body weights of
150–210 g each, at the beginning of experiment were used
in the current study. The animals were fed on a standard
laboratory food and water ad libitum. They were kept
under standard conditions of temperature and humidity.
All animal experiments received approval from the ethical
committee of Tanta Faculty of Medicine.
2.3. Experiment design
Rats were classiﬁed into 5 groups, 10 rats each.
Group I (control group): received 5 mmol/l citrate buffer.
Group II (genistein group): received 20 mg/kg genistein
daily.
Group III (diabetic group): this group included STZ-
induced diabetic animals.
Group IV (low dosage genistein treated group): diabetic
animals received genistein dosage 10 mg/kg/day.
Group V (high dosage genistein treated group): diabetic
animals received genistein dosage 20 mg/kg/day.
2.4. Induction of diabetes
Diabetes was induced with single intraperitonium
injection of STZ, 60 mg/kg. To overcome the expected hypo-
glycemia, the animals were allowed to drink 5% glucose
solution overnight. After 48 h, the diabetes was conﬁrmed
by measuring fasting blood glucose levels from a tail vein
using an Ames One Touch Glucometer (LifeScan; Johnson
and Johnson, New Brunswick, NJ, USA). Only animals with
plasma glucose level above 200 mg/dL [28,30] were chosen
for the experiment. Treatment of diabetic rats with genis-
tein (groups IV and V) started 1 week post STZ injection.
Low dose probably reﬂects the daily genistein intake in soy
enriched diet in human [31]. All rats were not treated with
insulin throughout the study which lasted for 4 weeks after
induction of diabetes.
Through the experiment, ﬂuid intake was estimated and
ﬁnally, the rats were weighed, fasted overnight without
water deprivation and then sacriﬁced under ether inhala-
tion. Histological, immunohistochemical, morphometrical
and biochemical studies were conducted.
2.5. Histological and immunohistochemical study
Small pieces were obtained from pancreatic tail, ﬁxed
in 10% buffered formalin and processed for examination by
light microscopy that were subjected to [32,33].1- Hematoxylin and eosin (H&E).
2- Immunohistochemical staining for detection of insulin
antibody using the avidin–biotin peroxidase system.
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Table 1
Body weight (g) and ﬂuid intake (ml) in control and experimental groups.
Groups Body weight (g) Fluid intake (ml)
Group I 208 ± 3.6 31 ± 3
Group II 204 ± 4.1 39 ± 2
Group III a135 ± 2.3 a169 ± 7
Group IV 148 ± 0.3 137 ± 4
Group V b187 ± 2.9 b76 ± 2
Values are expressed as mean ± SD.
Histogram 1. Shows a signiﬁcant reduction in body weights in group III in
comparing with the control one (P > 0.05). After induction
of diabetes (group III), signiﬁcant loss of body weights and
increased ﬂuid intake were observed compared to con-
trol one (P < 0.001). Treatment with low dosage genisteina P < 0.001 as compared to control.
b P < 0.001 as compared to diabetic.
The primary antibodies used were mouse monoclonal
insulin antibodies (Medico Company, Egypt) at a dilution
of 1:100 that incubated with slides for 1 h at room temper-
ature. Then, the sections were counterstained with Meyer’s
hematoxylin.
For electron microscopy, thin slices of pancreas were
ﬁxed in 5% cold glutaraldehyde then washed three times
with phosphate buffer (pH 7.2) and post ﬁxed in cold
osmium tetroxide for 2 h. Subsequently, the specimens
were washed in buffer, dehydrated in a graded series
of alcohol and embedded in Epon. Ultrathin sections
(50–80 nm)  were cut with ultramicrotome, collected on
copper grids and stained with uranyl acetate and lead
citrate to be examined [34] by (JEM-1010) transmission
electron microscopy (TEM; Jeol, Tokyo, Japan) in Tanta Uni-
versity Electron Microscopy Unit.
2.6. Morphometrical study
The image analyzer computer system Leica Qwin 500 in
the Central laboratory, Faculty of Medicine, Tanta Univer-
sity was used to evaluate:
1- Number of islets/each pancreatic section.
2- Diameter of the islets.
3- Number of -cells/islet.
Examination was performed at different magniﬁcations
in the non-serial pancreatic sections using H&E. The -
cells were determined by direct counting method at 1000×
magniﬁcation. The number of islets was quantiﬁed at these
sections at 40× magniﬁcation. Data were then collected in
an Excel sheet and submitted to statistical analysis [35].
2.7. Biochemical study
Venous blood samples from all animals were collected
in heparinized tubes and centrifuged at 3000 rpm for
15 min  to separate plasma used for the determination of
[36]:
1- Glucose levels by the glucose oxidase method (kit pur-
chased from Stanbio laboratory, USA).2- Insulin level by using an enzyme-linked immunosor-
bent assay, ELISA (kit purchased from DRG International
Inc., California, USA).comparison with group I and a signiﬁcant increase in group V compared
to group III. Note nonsigniﬁcant affection of body weights in group IV
comparing with group III.
2.8. Statistics
Statistical analysis were performed using SPSS program,
version 17 (IBM Corporation, Somers, New York, USA) in
the form of mean (X) ± standard deviation (SD). A one-way
analysis of variance (ANOVA) was used for calculation of
differences between the groups’ means. P < 0.05 was con-
sidered statistically signiﬁcant.
3. Results
3.1. Body weight and ﬂuid intake
Alterations in body weights and ﬂuid intake in con-
trol and experimental groups were shown in Table 1 and
Histograms 1 and 2. No signiﬁcant difference in these
parameters in rats treated with genistein alone (group II)Histogram 2. Shows a signiﬁcant increase of ﬂuid intake in group III com-
pared to group I and a signiﬁcant reduction in group V compared to group
III.  Note nonsigniﬁcant affection of ﬂuid intake in group IV in comparison
to group III.
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Fig. 1. A section of control pancreas showing large well-deﬁned islet of
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3.2.2. Diabetic group (group III)
Pancreatic sections stained with H&E of diabetic group
showed few ill-deﬁned islets of Langerhans. Marked his-
tological alterations in the structure of the islets wereangerhans (arrow) composed of cords of endocrine cells with rounded
esicular nuclei and pale acidophilic cytoplasm (stars). Note small blood
apillaries (C). H&E, scale bar 50 m.
group IV) did not signiﬁcantly prevent these changes.
owever, high dosage genistein (group V) signiﬁcantly
ncreased body weights and reduced ﬂuid intake as com-
ared to diabetic group (P < 0.001).
.2. Histological and immunohistochemical results
.2.1. Control & genistein groups (groups I and II)
Pancreatic sections stained with H&E of control and
enistein treated rats showed large, regular and well
eﬁned islets of Langerhans which represented the
ndocrine portion of pancreatic lobules. They appeared as
ale staining areas surrounded by thin capsule of connec-
ive tissue scattered in between the exocrine parenchyma.
he islets arranged in anastomosing branching cords with
lood capillaries in between and consist of clusters of
olygonal cells had pale acidophilic cytoplasm and central
ounded vesicular nuclei (Fig. 1).
ig. 2. A section of control pancreas showing well-deﬁned islets of Langer-
ans (arrows) with strong immunoreactions for insulin antibody in their
-cells. Insulin immunostain, scale bar 200 m.Fig. 3. A higher magniﬁcation of the previous ﬁgure showing highly pos-
itive insulin antibody staining (arrows) in the cytoplasm of the majority
of  cells, -cells. Insulin immunostain, scale bar 50 m.
Regarding the immunohistochemistry, areas of dark
brown staining (strong positive) for insulin antibody were
seen in islet -cells cytoplasm which form the major cells
population of the islets (Figs. 2 and 3).
Ultrastructurally, islet -cells appeared oval or polyg-
onal in shape with indistinct intercellular space had
euchromatic rounded nuclei and contained many charac-
teristic  granules in their cytoplasm. An electron lucent
halo space surrounded an electron dense core is charac-
teristic feature of the granules. The mitochondria, rough
endoplasmic reticulum (rER) and Golgi apparatus were
observed among them (Figs. 4 and 5).Fig. 4. An electron micrograph of control -cells with indistinct intercel-
lular space showing euchromatic rounded nuclei (N) and characteristic
  granules (Gr). Note short proﬁle round mitochondria (m) and Golgi
complex (G). ×2000.
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Fig. 5. An electron micrograph of a control -cell showing -granules
Fig. 7. A section of pancreas from the diabetic group showing a shrunkenwith an electron dense core surrounded by an electron lucent halo (Gr),
round electron dense mitochondria (m)  with arrows indicating elongated
mitochondria and rER. Note part of the nucleus (N). ×5000.
observed. They appeared shrunken and distorted with
marked loss of its cells and normal cellular cord arrange-
ment. Many islets cells revealed marked cytoplasmic
vacuolation and pyknotic nuclei and others showed a
deeply acidophilic cytoplasm with large darkly stained
nuclei (Figs. 6 and 7).
Immunohistochemical reactions revealed marked
reduction in immunoreactivity for insulin antibody inside
islet -cells and only a few -cells displayed minimal
insulin immunoreaction (Fig. 8).
The electron micrographs of pancreas of diabetic rats
showed remarkable changes in the islet -cells, most of
the cells exhibited marked loss of their granules in rariﬁed
cytoplasm leaving empty spaces or electron lucent areas.
Their nuclei showed variable changes, some appeared
dark electron dense and others showed marked periph-
eral aggregation of heterochromatin with irregular nuclear
envelope. Golgi apparatus was obviously dilated and the
Fig. 6. A section of pancreas from the diabetic group showing small islets
of  Langerhans (arrows) with loss of its normal cell cord arrangement.
Many cells show pyknotic nuclei (dotted arrows). H&E, scale bar 50 m.distorted islet of Langerhans with marked loss of its cells (arrow). Note
some cells with vacuolated cytoplasm (v) and large darkly stained nuclei
(star). H&E, scale bar 50 m.
mitochondria were vacuolated with loss of their cristae
and matrix. Congested blood capillaries were also seen. -
granules of some cells appeared with increased electron
lucent halo around small electron dense cores. Increasing
number of empty granules and small mitochondria were
also noted (Figs. 9 and 10).
3.2.3. Low dosage genistein treated group (group IV)
By H&E stain, sections of pancreas of diabetic rats
treated with low dosage genistein showed the simi-
lar changes as those in group III, the islets were still
shrunken and ill deﬁned with marked disturbance of cells
arrangement. Most cells appeared with marked cytoplas-
mic  vacuolation and pyknotic nuclei (Figs. 11 and 12).
Regardless, some islet -cells displayed mild insulin
immunopositivity, most of the cells were still negative for
insulin immunoreactivity (Fig. 13).The electron micrographs conﬁrmed the results shown
by light microscope as no obvious improvement in the
islet -cells was  observed. Most cells were still affected
Fig. 8. A section of pancreas from the diabetic group showing a small
islet of Langerhans with negative insulin immunoreactivity in its -cells
(arrow). Note a few -cells with minimal insulin immunoreaction (dotted
arrow). Insulin immunostain, scale bar 200 m.
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Fig. 9. An electron micrograph of pancreas from the diabetic group show-
ing -cells scattered inbetween congested blood capillaries (C) have
rariﬁed cytoplasm with electron lucent areas (stars), few secretory gran-
ules (Gr), dilated Golgi complexes (G) and vacuolated mitochondria (m).
Note small nuclei (N). × 3000.
Fig. 10. An electron micrograph of a -cell from the diabetic group show-
ing irregular shaped dark electron dense nucleus (N) and -granules with
increased electron lucent halo (Gr). Note an increased numbers of small
mitochondria (arrows) and empty granules (stars). ×2000.
Fig. 11. A section of pancreas from low dosage genistein treated group
showing shrunken distorted islets of Langerhans (arrows) contained few
cells with pyknotic nuclei (star). H&E, scale bar 50 m.Fig. 12. A section of pancreas from low dosage genistein treated group
showing a shrunken islet of Langerhans with vacuolated cytoplasm (v)
and  pyknotic nuclei (arrow) in its cells. H&E, scale bar 50 m.
and appeared shrunken with heterochromatic nuclei and
disrupted vacuolated cytoplasm that contained decreased
amount of  granules and destructed vacuolated mitochon-
dria. Moreover,  secretory granules in the cytoplasm of
some cells appeared either empty or with increased halo
spaces around less dense cores. Few cells appeared with
intact mitochondria and normal characteristic  granules
(Figs. 14–16).
3.2.4. High dosage genistein treated group (group V)
H&E stained pancreatic sections of the diabetic rats
treated with high dosage genistein, showed partial
improvement in the histological structure of its islets which
appeared more or less normal with an apparent increase
in their size. Some of its cells showed minimal cytoplas-
mic  vacuolation and pyknotic nuclei, while others were
improved having central vesicular nuclei with pale aci-
dophilic cytoplasm (Fig. 17).
Fig. 13. A section of pancreas from low dosage genistein treated group
showing an islet of Langerhans with negative insulin immunoreactivity
in majority of -cells (arrows). Note some -cells with positive insulin
immunoreaction (dotted arrow). Insulin immunostain, scale bar 50 m.
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Fig. 14. An electron micrograph of an islet -cells from low dosage genis-
tein  treated group showing multiple vacuoles (V) and decreased amount
Fig. 16. An electron micrograph of -cells from low dosage genistein
treated group showing one cell has dark nucleus with condensed chro-
matin (N), rER and granules either empty (arrows) or with increased halo
spaces (Gr). Note other cells with normal characteristic  granules (dotted
arrow) and mitochondria with intact cristae (m). ×2000.of -granules (Gr) in the disrupted cytoplasm. Note swollen vacuolated
mitochondria (m)  and irregular nuclei (N). ×3000.
Regarding the immunohistochemistry, different sizes
of islets of pancreas were observed with increasing
immunoreaction to insulin antibody in -cells in compar-
ison to diabetic group (Figs. 18 and 19).
Ultrastructurally, -islet cells appeared containing
euchromatic nuclei with clumps of heterochromatin and
an increase in the number of  granules, there were of
normal structure as control, having dense core surrounded
by lucent halo space of different sizes. Numerous rounded
and elongated electron dense mitochondria were observed
throughout the cytoplasm as well as proliferating rER
(Figs. 20 and 21). However, some cells were still affected
and had irregular shaped heterochromatic nuclei and -
granules with increased halo spaces. rER appeared dilated
(Fig. 22).
Fig. 15. An electron micrograph of a -cell from low dosage genistein
treated group showing decreased -granules (Gr), vacuolated mitochon-
dria (m)  in disrupted cytoplasm and a normal nucleus (N). ×5000.
Fig. 17. A section of pancreas from high dosage genistein treated group
showing an apparent increase in the size of an islet has more or less normal
cells (arrows). Note a few cells with vacuolated cytoplasm (v) and pyknotic
nuclei (dotted arrows). H&E, scale bar 50 m.
Fig. 18. A section of pancreas from high dosage genistein treated group
showing appearance of different sizes islets of pancreas with increas-
ing insulin immunoreactivity (arrows). Insulin immunostain, scale bar
200  m.
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Table  2
Number of islets/pancreas (N/10 mm2), diameter of islets (m) and number of -cells/islet (N/1000 m2) in control and experimental groups.
Groups Number of islets/pancreas (N/10 mm2) Diameter of islets (m) Number of -cells/islet (N/1000 m2)
Group I 18.79 ± 0.719 130.74 ± 10.945 10.45 ± 0.561
Group  II 18.63 ± 0.731 134.39 ± 12.841 10.63 ± 0.738
Group  III a4.32 ± 0.395 a61.87 ± 5.319 a2.78 ± 0.179
Group  IV 6.98 ± 0.245 79.38 ± 3.709 4.22 ± 0.636
Group  V b11.42 ± 0.611 b102.76 ± 7.986 b7.89 ± 0.473
Values are expressed as mean ± SD.
a P < 0.001 as compared to control.
b P < 0.001 as compared to diabetic.
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Fig. 21. An electron micrograph of an islet of pancreas from high dosageig. 19. A higher magniﬁcation of the previous ﬁgure showing an islet of
angerhans with increasing insulin immunoreactivity in cytoplasm of its
-cells (arrows). Insulin immunostain, scale bar 50 m.
.3. Morphometric results
Morphometric results (Table 2 and Histograms 3, 4
nd 5) showed a signiﬁcant reduction in the number of
slets/pancreas, islet diameter and number of -cells/islet
n diabetic group (group III) compared to that of control one
P < 0.001). However, these parameters were signiﬁcantly
ncreased in high dosage genistein treated group (group V)
P < 0.001), but did not signiﬁcantly change in rats treated
ith low dose of genistein (group IV) compared to diabetic
roup. Nonsigniﬁcant difference (P > 0.05) was observed in
ig. 20. An electron micrograph of an islet of pancreas from high dosage
enistein treated group showing euchromatic nuclei (N) of many -cells
ith increasing amount of  secretory granules (Gr). Note numerous elec-
ron dense mitochondria (arrows) and proliferating rER. ×1500.genistein treated group showing -cells studded with characteristic 
secretory granules (Gr), numerous intact mitochondria (m). Note euchro-
matic nuclei (N). ×2500.
these parameters in genistein group (group II) in compari-
son to the control.
3.4. Biochemical resultsTable 3 and Histograms 6 and 7 showed nonsigniﬁ-
cant difference (P > 0.05) in plasma glucose and insulin
levels of the control and genistein groups (groups I and II
respectively). In comparison with previous groups, levels
Fig. 22. An electron micrograph of a -cell from high dosage genistein
treated group showing -granules with increased halo spaces (Gr), dilated
rER and mitochondria (m). Note part of the nucleus (N). ×4000.
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Histogram 3. Shows a signiﬁcant reduction of number of islets/pancreas
in  group III in comparison to group I and a signiﬁcant increase in group V
when compared with group III. Note nonsigniﬁcant affection of number
of islets/pancreas in group IV comparing with group III.
Histogram 4. Shows a signiﬁcant reduction of islet diameter in group III in
Table 3
Plasma glucose level (mg/dL) and insulin level (U/ml) in control and
experimental groups.
Groups Plasma glucose level (mg/dL) Insulin level (U/ml)
Group I 94.8 ± 6.21 53.6 ± 1.4
Group II 102.5 ± 2.9 49.2 ± 4.3
Group III a294.2 ± 11.4 a10.4 ± 1.87
Group IV 233.7 ± 4.9 13.1 ± 4.62
Group V b178.5 ± 9.3 b32.9 ± 4.62
Values are expressed as mean ± SD.
a P < 0.001 as compared to control.
b P < 0.001 as compared to diabetic.
Histogram 6. Shows a signiﬁcant increased glucose level in group III in
Diabetes mellitus is one of the most common, danger-comparison to group I and a signiﬁcant increase in group V in comparison
with group III. Note nonsigniﬁcant affection of islet diameter in group IV
comparing with group III.
of fasting plasma glucose were signiﬁcantly higher and
insulin levels were signiﬁcantly lower in diabetic group
(group III) (P < 0.001). High dosage genistein treatment
(group V) signiﬁcantly decreased plasma glucose levels
and signiﬁcantly increased insulin levels (P < 0.001) as
Histogram 5. Shows a signiﬁcant reduction of number of -cells/islet in
group III when compared with group I while it signiﬁcantly increased in
group V in comparison with group III. Note nonsigniﬁcant affection of
number of -cells/islet in group IV comparing with group III.comparison to group I and a signiﬁcant reduction in group V in comparison
with group III. Note nonsigniﬁcant affection of glucose level in group IV
comparing with group III.
compared with the diabetic group, but low dosage genis-
tein treatment (group IV) did not signiﬁcantly reduce
plasma glucose levels as well as did not signiﬁcantly
increase insulin levels.
4. Discussionous, costly health problems in the twenty-ﬁrst century. An
increase in sedentary life-style, consumption of energy-
rich diet and obesity are some of the factors causing the rise
Histogram 7. Shows a signiﬁcant decreased insulin level in group III in
comparison to group I and a signiﬁcant increase in group V when com-
pared to group III. Note nonsigniﬁcant affection of insulin level in group
IV comparing with group III.
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n the number of diabetics. Controlling hyperglycemia and
xidative stress inhibition have been suggested as impor-
ant measures in the management of DM [35,37].
Soy isoﬂavone genistein may  provide new, low cost,
reater potential oral hypoglycemic compounds. There-
ore, this study was done to investigate the effect of
ifferent doses of soy genistein on histological, immuno-
istochemical and morphometrical changes of pancreatic
slets -cells and correlate these effects with plasma glu-
ose and insulin levels in diabetic rats.
In the current study, all results of genistein group (group
I) were similar to the control one indicating safety and non-
oxicity of genistein administration. These observations
ere consistent with results of previous researchers [38]
ho stated that, there is no any observed toxicity of genis-
ein dosage up to 120 mg/kg/day in rats which is six times
ore than the highest dosage used in this work.
Experimental diabetes induced by STZ produced severe
oss of body weights and an increase of ﬂuid intake which
enerally occur in diabetes. Dehydration and catabolism of
ats as well as proteins with increased catabolic reaction
re major causes of these signs [3].
Our study revealed that STZ altered islet morphol-
gy which appeared ill deﬁned, damaged and shrunken
ith marked vacuolated cytoplasm and pyknotic nuclei
n most of its endocrine cells in association with marked
ecrease in insulin antibody positivity in islet -cells. These
esults are in agreement with those reported previously
39–41].
Moreover, ultrastructural results revealed heterochro-
atic nuclei, decreased secretory granules, mitochondrial
acuolation and fragmentation as well as dilatation of the
ER and Golgi apparatus and multiple vacuoles in the -
ells that in consistence with other investigators [41]. In
ddition, degranulation of most -cells and increased halo
paces of granules of other cells were in conforming with
he results of other studies [42,43] who found similar
ltrastructural changes in rat pancreatic -cells induced
y STZ.
Pancreatic -cells toxicity induced by STZ has been
nvestigated in several experimental models and is thought
o be as a result of production of reactive oxygen species
hat led to lipid peroxidation and DNA damage [41–44].
As a result of increasing lipid peroxidation, lipid-
ontaining membranes as Golgi and rER membranes were
ilated suggesting the observed cytoplasmic vacuolation of
he islet cells seen in the present study. The observed vac-
olated mitochondria led to disturbance of mechanism of
ntioxidation, explaining mitochondrial limited ability to
vercome the oxidative stress in -cells [10].
The histological changes come hand by hand with
orphometric results which showed a signiﬁcant reduc-
ion in number of islets and islet diameter as well as
umber of -cells/islet in diabetic group compared with
he control one. In addition, these observations were
onsistent with the biochemical ﬁnding of a signiﬁcant
ncrease in serum glucose levels and a signiﬁcant decrease
n insulin secretion. These results were in agreement
ith previous studies [45,46] that reported signiﬁcant
eduction in the numerical density of islets, volume of
slets, and volume of -cells in the untreated diabeticopy and Ultrastructure 3 (2015) 108–119 117
group of rats when compared with the control one.
Previous studies [8,47] reported the same changes in
blood glucose and insulin levels in experimental diabetic
animals.
The observed degeneration of the islet cells together
with signiﬁcant reduction in the numerical density of islets
as well as the decrease in insulin antibody positivity in the
diabetic animals, explained decreased insulin level noted
in these animals. Consequently, the observed elevation of
blood glucose level in this group may  be the result of
decreasing insulin level.
Diabetes has been shown to be a state of free radi-
cals overproduction resulting from hyperglycemia. Factors
that attributed to the formation of free radicals may
include not only elevated non-enzymatic and autooxida-
tive glycosylation, but also metabolic stress as a result of
alterations in energy metabolism, inﬂammatory media-
tors levels and the status of antioxidant defense [41,47].
The resultant decrease in both antioxidant capacity and
insulin activity/sensitivity led to commonly observed dia-
betic complications [47,48].
Comparing with diabetic group, not low dosage treated
genistein group (group VI), which corresponding to daily
genistein intake after soy enriched diet in humans [31]
but high dosage treated genistein group (group V) showed
a signiﬁcant increase in body weights accompanied by
a signiﬁcant decrease in ﬂuid intake. These results were
consistent with those of previous study in rats adminis-
tered soybean seed 400 mg/kg [3] and in mice [49] who
reported that soybean by its contents of high percentage
of protein and isoﬂavone, increases metabolic processes
in body.
In the present study, genistein causes dose-dependent
amelioration of toxic effects of STZ on pancreatic -cells.
Low dosage genistein treated group (group IV) failed to
improve the morphological changes in the islets as well
as insulin immunoreactivity induced by STZ while, admin-
istration of high dosage genistein (group V) resulted in
partial improvement of the islets and -cells associated
with increased insulin immunoreactivity.
These results have been supported by electron micro-
scopic ﬁndings that revealed appearance of  islets cells
with euchromatic nuclei and retention of most -cells to
their normal structures with increasing number of normal
 granules, there were of normal structure as control in
group V than those observed in group IV.
Studies on whether genistein by itself has an effect on
diabetes are very limited and there have been no mor-
phological studies to date examining the pancreatic -cells
ultrastructure in STZ-diabetic rats treated with isoﬂavone
genistein.
Genistein has been reported to be protective agent for
diabetes by regulation of oxidative stress and inﬂammation
as it decreases lipid peroxidation, inhibits cyclooxygenase
expression and myeloperoxidase activity as well as reacts
with free radicals and neutralizes their effects [50,51].
Other researchers stated that the efﬁciency of genistein as
antioxidant is achieved only at high doses (ranging from
25 to 100 m) and it has not this property at physiolog-
ical doses as its plasma level through diet intake is not
more than 10 m in both humans and animals [52,53]. The
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antioxidant effect of soy isoﬂavones protects cell mem-
branes from damage and increases their stability, which
contributes to the increased insulin sensitivity [54].
Moreover, the observed morphometric results con-
ﬁrmed the histological one. In animals treated with low
dose genistein (group IV), no signiﬁcant changes in the
number of islets and islet diameter as well as number of -
cells/islet were observed compared with the diabetic one.
In contrast, high dosage genistein treatment (group V) was
able to reduce STZ islet cells loss and showed signiﬁcant
increase in these parameters.
Accordingly, previous study [14] have shown that genis-
tein is an antidiabetogenic agent through its effect on
proliferation of -cells and insulin secretion by glucose
stimulation regardless of its efﬁciency as antioxidant, an
estrogen receptor agonist and tyrosine kinase inhibition.
In addition, other data have demonstrated that genistein
can act as -cells growth factor in vivo suggesting a novel
mechanism for antidiabetic effect of this agent [53]. This
regeneration of the -cells is probably due to the fact that
pancreas contains stable (quiescent) cells which have the
capacity of regeneration [35]. Therefore, the surviving cells
can proliferate to replace the lost cells.
Other researchers reported that teucrium polium crude
extract is able of regeneration of islets of Langerhans and
enhancing of insulin secretion [55]. In addition, glabridin
has shown the same effects [45].
Our data showed that genistein at high dose (group V)
but not in low dose (group IV) can improve both glucose
and insulin levels in rats with STZ induced islets damage.
This was consistent with results of other researchers who
have demonstrated marked improvement in blood glu-
cose and insulin levels after genistein intake for diabetic
animals [25,53,56]. Consistent with our observations, a pre-
vious study has demonstrated lowering in fasting blood
glucose, increasing in plasma insulin and C-peptide and
enhancement of insulin staining in the pancreatic islets
of STZ-induced diabetic mice supplemented with genistein
(200 mg/kg) diets for 9 weeks [57].
The observed increased insulin level and decreased
blood glucose concentration may  be due to the ame-
lioration of the histological structure of -cells together
with increased insulin immunoreactivity and signiﬁcant
increase in the numerical density of islets that retained the
ability to synthesize and secrete insulin.
An increased number of mitochondria that were noted
in cytoplasm of -cells in group V may  reﬂect compen-
satory adaptation to produce much energy in response of
glucose stimulation to maintain glucose homeostasis for
synthesis and secretion of insulin [58].
In conclusion, the present study showed that genis-
tein has a protective effect on pancreatic -cells toxicity
induced by STZ in a dose dependent manner. High dosage
genistein possesses the ability to regenerate -cells that
results in increasing the lowered serum insulin and conse-
quently decreasing high serum glucose in diabetic rats.Conﬂict of interest
The authors declare no conﬂict of interest.
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